Skip to main content

Home/ Cerebral Palsy/ Group items tagged pharmacokinetics

Rss Feed Group items tagged

Lee Vander Loop

Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and M... - 0 views

  •  
    Completed study sponsored by University Hospital, Ghent assessing Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation. Trial aims to compare the pharmacokinetics of omeprazole administered through the gastrostomy tube as a suspension in pediatric patients with cerebral palsy and mental retardation versus the pharmacokinetics of omeprazole administered as a multi-unit-pellet system (MUPS®).
Lee Vander Loop

A Pharmacokinetics (Blood Levels), Pharmacodynamics (How the Drug Acts on the Body) and... - 0 views

  •  
    Study is to evaluate the pharmacokinetics (blood levels), pharmacodynamics (how the drug acts on the body), and the safety of rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in new borns and pre-term infants (less than 44 weeks of age).
Lee Vander Loop

Multi Dose Inositol Pharmacokinetics and Outcomes in Premature Infants (INS-2) Pilot Study - 0 views

  •  
    To evaluate the safety and multi-dose pharmacokinetics and dose ranging of intravenous followed by enteral myo-inositol (inositol) given at three dosage levels in extremely preterm neonates.
Lee Vander Loop

Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis - 0 views

  •  
    Completed study comparing the blood drug levels of two prescribed medications, Immediate-release omeprazole 40 mg powder and delayed-release omeprazole 40 mg capsule to determine which drug is better absorbed in patients with a slow stomach emptying (gastroparesis). Delayed-release omeprazole has a protective coating to prevent the drug omeprazole from being neutralized by stomach acid. Immediate-release omeprazole has sodium bicarbonate (antacid) which neutralizes the stomach acid, eliminating the need for a protective coating. Immediate-release omeprazole suspension may have a more rapid pharmacokinetic profile and greater overall drug absorption in gastroparesis.
Lee Vander Loop

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subje... - 0 views

  •  
    Completed study assessed the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.
Lee Vander Loop

Drug Trial for Children with Partial Onset Seizures - DukeHealth.org - 0 views

  •  
    Duke University and Multicenter, Open-label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Lacosamine (LCM) Oral Solution (syrup) as Adjunctive Therapy in Children with Partial Onset Seizures. This study is being done to test the safety of the study drug Lacosamide (LCM) syrup and how the body processes it.
Lee Vander Loop

Pilot Study of Bumetanide for Newborn Seizures - 0 views

  •  
    Study to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
Lee Vander Loop

Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants - China Medical ... - 0 views

  •  
    A recent study using high-dose rhEpo (3000 U rhEpo/kg body weight at birth) for neuroprotection in very preterm infants revealed that no signs of adverse effects of early high-dose rhEpo treatment in very preterm infants were identified. Contrary to this, a recent study in PVL of a rat model revealed that using a low dose rhEpo (50-100 U/kg) was effective in the treatment of brain damage induced by hypoxia-ischemia and did not affect normal oligodendrocyte maturity. On this basis, the researchers intent to investigate (1) whether low-dose rhEpo (100 U/kg) or high-dose rhEpo (3,000 U/kg) given to very preterm infants (gestation age < 32 weeks) immediately after birth and subsequently during the first 2 days is safe and possesses neuroprotective properties;(2) whether there are gender differences in response to the hypoxia-ischemic insult and EPO treatment; (3)the pharmacokinetics of low dose and high dose rhEPO.
Lee Vander Loop

Dexmedetomidine in Seizure Patients - 0 views

  •  
    The investigators study aims to investigate the pharmacokinetic and pharmacodynamic differences of dexmedetomidine between patients receiving and not receiving enzyme-inducing anticonvulsant therapy and to identify a potential mechanism for these differences.
Lee Vander Loop

Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity - 0 views

  •  
    NICHD study is to determine how fast the drug oral baclofen is cleared from the body, the correct dose, and long-term safety and efficacy for children with spasticity.
Lee Vander Loop

Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity - 0 views

  •  
    Information on research and on going clinic trial being sponsored by Eunice Kennedy Shriver National Institute of Child Halth and Human Development (NICHD) to determine safety, doseage and efficacy in the use of Oral Baclofen with children with cerebral palsy
Lee Vander Loop

Pregabalin in Pediatric Patients with Partial Onset Seizures - DukeHealth.org - 0 views

  •  
    Duke University Clinical trial and study to evaluate the safety, tolerability, and pharmacokinetics of the study drug Pregabalin in pediatric patients with partial onset seizures in addition to measuring how much pregabalin is in your child's blood and urine after he/she takes the study drug
Lee Vander Loop

University of Virginia Health System - Baclofen Efficacy and Safety Trials - 0 views

  •  
    Baclofen Efficacy and Safety Trials - Pediatric Pharmacokinetic and Pharmacodynamic Study of Oral Baclofen for the Treatment of Spasticity Associated with Cerebral Palsy (BEST-PK/PD)
Lee Vander Loop

Neonatal Erythropoietin in Asphyxiated Term Newborns - 1 views

  •  
    Future planned study being conducted by the University of California to determine the safety and pharmacokinetics of moderate to high doses of erythropoietin in newborn infants with birth asphyxia.
Lee Vander Loop

Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth - 2 views

  •  
    Eunice Kennedy Shriver National Institute of child Health and Human Development (NICHD) Study to evaluate the safety of high-dose Erythropoietin (Epo) in infants who did not get enough oxygen during birth. Erythropoietin is a hormone normally found in the body that may protect brain cells from damage due to lack of oxygen.
1 - 15 of 15
Showing 20 items per page